All posts tagged "GILD"
-
1.3K1BiotechGlaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn (OTCMKTS: CYDY) as a Takeover Target
GSK (NYSE: GSK) has a new mission and that mission is to go after major medical conditions that have no treatment. The...
-
1.0K1BiotechVeru’s (NASDAQ: VERU) Repurposed COVID-19 Drug Facing Uphill Battle for EUA
At first glance Veru, Inc.’s (NASDAQ: VERU) COVID-19 therapy phase 3 top line results were notable but their battle for an emergency...
-
896BiotechThe 3CL Secret to Pfizer’s and Todos Medical’s Success
Pfizer’s (NYSE: PFE) PAXLOVID has risen to prominence as the top COVID-19 antiviral in the world. The speed at which they rose...
-
9761BiotechPicking a Bottom in CytoDyn – Right Now
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
-
3.1KBiotechAtea Failure Leaves Todos Medical (TOMDF) Last Man Standing in Oral Antivirals
The big news circulating this week was of Atea Pharmaceuticals’ (NASDAQ: AVIR) COVID-19 antiviral clinical trial failure, which instantly plummeted the stock...
-
952BiotechCytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle
Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case...
-
8202BiotechCytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
-
1.0KBiotechEnzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...
-
958BiotechTodos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
-
3.0KBiotechAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...